Market Research Report
Ragweed Allergy Therapeutics Market with COVID-19 Impact Analysis, By Drug Type, By Distribution Channel, and By Region - Size, Share, & Forecast from 2021-2027
|Published by||AnalystView Market Insights||Product code||980665|
|Published||Content info||180 Pages
Delivery time: 2-3 business days
|Ragweed Allergy Therapeutics Market with COVID-19 Impact Analysis, By Drug Type, By Distribution Channel, and By Region - Size, Share, & Forecast from 2021-2027|
|Published: December 1, 2020||Content info: 180 Pages||
The global Ragweed Allergy Therapeutics market was valued at USD 1,068.2 million in 2020, growing with 5.21% CAGR during the forecast period, 2021-2027.
Ragweed is a kind of flowering plant that originates from the genus Ambrosia in the aster family. Ragweed allergy occurs when our human immune system shows an inappropriate response. The immune system helps to fight against bacteria and viruses. The allergies caused by the ragweed can be treated with medications and antihistamines.
The ragweed allergy therapeutics market is estimated to witness significant growth in the next few years. The growing demand for advanced therapies for ragweed allergy treatment is mainly contributing to market growth. Additionally, changes in environmental conditions and expanding pollution are leading to the growth of ragweed allergy therapeutic treatment. According to the Asthma & Allergy Foundation of America (AAFA), over 23 million population in the U.S. have shown symptoms of ragweed pollen allergies in the late summers. Such symptoms make life miserable for those with allergies that cause asthma symptoms for allergic asthma individuals.
According to a research study, climatic changes tend to cause ragweed allergy and impact a larger population across the world. For example, based on data from the American College of Allergy, there are over 17 species of ragweeds present in the U.S. these allergies can be treated with proper therapeutics treatment. In addition, several companies are increasing their focus on clinical trials, strategic partnerships, and spending on R&D developments of advanced drugs, & other novel therapies. The drug authorizations and strategic collaborative research are anticipated to significantly offer ample growth opportunities for the market.
North America held the largest market share in 2019. Key players are focusing on getting product approvals & clinical trials of drugs for treating ragweed allergies. For example, the U.S. Food and Drug Administration (FDA) has granted two novel prescription medications, Grastek, and Ragwitek for the treatment of ragweed allergies. All these initiatives are anticipated to boost regional growth. a significant rate over the forecast period. The European market is expected to foresee significant growth due to initiatives taken by key companies for the treatment of ragweed allergy. For example, in Europe, ALK has submitted a registration for 'Ragweed SLIT-tablet' in 2017.
The ragweed allergy therapeutics market is moderately competitive in nature with the presence of international and local players. Key players in the market engage in strategic collaboration, and R&D activities to remain competitive in the industry. For example, Austria-based biotech companies, VTU Technology, and Biomay AG collaborate to produce recombinant allergens.
Key features of the study:
This proposed research study on Ragweed Allergy Therapeutics market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2020-2027), considering 2019 as the base year
The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Ragweed Allergy Therapeutics market
The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Ragweed Allergy Therapeutics market
Impact of COVID-19 on Ragweed Allergy Therapeutics market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Ragweed Allergy Therapeutics market post-COVID will also be covered.
In order to give the users of this report a comprehensive view on the Ragweed Allergy Therapeutics market, we have also included competitive landscape and key innovator analysis for the Ragweed Allergy Therapeutics market.
The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and end-user's attractiveness.
The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Ragweed Allergy Therapeutics market.
In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new product launch, research & development, regional expansion of major participants involved in the Ragweed Allergy Therapeutics market on global as well as regional level.
The global Ragweed Allergy Therapeutics market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RAGWEED ALLERGY THERAPEUTICS MARKET KEY PLAYERS
Astellas Pharma Inc.
Thermo Fisher Scientific Inc.
Siemens Healthcare Private Limited
Omega Diagnostics Group PLC
HYCOR Biomedical, Inc.
Lincoln Diagnostics, Inc.
HOB Biotech Group Corp Ltd.
Hitachi Chemical Diagnostics, Inc.
Immunomic Therapeutics, Inc.
GLOBAL RAGWEED ALLERGY THERAPEUTICS MARKET, BY DRUG TYPE
GLOBAL RAGWEED ALLERGY THERAPEUTICS MARKET, BY DISTRIBUTRION CHANNEL
GLOBAL RAGWEED ALLERGY THERAPEUTICS MARKET, BY REGION
Rest of Europe
Rest of APAC
Rest of LATAM
The Middle East and Africa
United Arab Emirates
Rest of MEA
List of Tables
List of Figures